Neuren Pharmaceuticals (ASX:NEU) received its first sales milestone payment of $50 million for the first year that the net sales of Rett syndrome drug Daybue exceeded $250 million in North America, according to a Friday filing with the Australian bourse.
The company's Nasdaq-listed partner Acadia Pharmaceuticals reported $348.4 million net sales of the drug in the US in 2024, the filing said.
The company will receive the second milestone payment from commercialization of the drug when net sales exceed $500 million, according to the filing.
Neuren Pharmaceuticals shares fell 6% in afternoon trade Friday.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.